Dollars and antisense for Duchenne muscular dystrophy
| العنوان: | Dollars and antisense for Duchenne muscular dystrophy |
|---|---|
| المؤلفون: | Peter B. Kang, Carla D. Zingariello |
| المصدر: | Neurology. 90:1091-1092 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, biology, Morpholino, business.industry, Duchenne muscular dystrophy, medicine.disease, Bioinformatics, Eteplirsen, Deflazacort, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Prednisone, biology.protein, Medicine, Neurology (clinical), Muscular dystrophy, business, Dystrophin, 030217 neurology & neurosurgery, medicine.drug |
| الوصف: | The world has changed for patients with Duchenne muscular dystrophy (DMD). Despite numerous important refinements in therapy over prior decades, a US Food and Drug Administration-approved therapy remained elusive until 2016. Now there are 2 such therapies, eteplirsen and deflazacort, in addition to prednisone, which has been used off-label for many years. However, controversies abound for both new treatments. Both are costly, and the pricing of deflazacort in particular has drawn criticism because it is a corticosteroid that has been in widespread use outside the United States for many years.1 |
| تدمد: | 1526-632X 0028-3878 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::7d122e311334b432dd16056e5f136299Test https://doi.org/10.1212/wnl.0000000000005669Test |
| رقم الانضمام: | edsair.doi...........7d122e311334b432dd16056e5f136299 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1526632X 00283878 |
|---|